Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$124.67
0.240.19%
À la fermeture: -
$123.74
-0.93-0.75%
Après les heures de négociation: 7:16 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Abbott Laboratories Corp a un objectif de cours consensuel de 567,61 $ basé sur les notes de 38 analystes. Le plus haut est de 1 350 $ émis par HSBC le 10 mai 2024<. Le plus bas est de 100 $ émis par Deutsche Bank le 5 août 2024. Les 3 dernières notations d'analystes ont été publiées par New Street Research, Goldman Sachs et Deutsche Bank respectivement le 6 août 2024, le 5 août 2024 et le 5 août 2024. Avec un objectif de cours moyen de 118,33 $ entre New Street Research, Goldman Sachs et Deutsche Bank, il existe une hausse implicite de 0,21 % pour Abbott Laboratories Corp à partir de ces notations d'analystes les plus récentes.
Sociétés d'analyse émettant des recommandations1
Barclays
Raymond James
Evercore ISI Group
RBC Capital
Wells Fargo
1calculé à partir des notes des analystes
Notes d'analystes pour Abbott Laboratories
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/17/2025 | — | Barclays | $159 → $162 | Maintains | Overweight | |||
10/16/2025 | — | Raymond James | $141 → $146 | Maintains | Outperform | |||
10/16/2025 | — | Evercore ISI Group | $144 → $142 | Maintains | Outperform | |||
10/16/2025 | — | RBC Capital | $147 → $147 | Reiterates | Outperform → Outperform | |||
10/16/2025 | — | Wells Fargo | $142 → $146 | Maintains | Overweight | |||
10/15/2025 | — | BTIG | $145 → $145 | Reiterates | Buy → Buy | |||
10/10/2025 | — | Benchmark | → $145 | Initiates | → Buy | |||
10/07/2025 | — | Evercore ISI Group | $140 → $144 | Maintains | Outperform | |||
07/18/2025 | — | Citigroup | $157 → $155 | Maintains | Buy | |||
07/18/2025 | — | Wells Fargo | $147 → $142 | Maintains | Overweight | |||
07/18/2025 | — | Raymond James | $142 → $141 | Maintains | Outperform | |||
07/18/2025 | — | Mizuho | $140 → $135 | Maintains | Neutral | |||
07/18/2025 | — | Jefferies | $143 → $145 | Upgrade | Hold → Buy | |||
07/18/2025 | — | BTIG | $148 → $145 | Maintains | Buy | |||
07/17/2025 | — | Evercore ISI Group | $145 → $140 | Maintains | Outperform | |||
07/16/2025 | — | Mizuho | $130 → $140 | Maintains | Neutral | |||
07/15/2025 | — | RBC Capital | $145 → $147 | Maintains | Outperform | |||
07/15/2025 | — | Morgan Stanley | $127 → $137 | Maintains | Equal-Weight | |||
07/14/2025 | — | BTIG | $145 → $148 | Maintains | Buy | |||
07/09/2025 | — | Citigroup | $155 → $157 | Maintains | Buy | |||
07/08/2025 | — | Evercore ISI Group | $140 → $145 | Maintains | Outperform | |||
06/20/2025 | — | Jefferies | $137 → $143 | Maintains | Hold | |||
04/17/2025 | — | BTIG | $140 → $145 | Maintains | Buy | |||
04/17/2025 | — | Bernstein | $138 → $144 | Maintains | Outperform | |||
04/17/2025 | — | Raymond James | $132 → $142 | Maintains | Outperform | |||
04/17/2025 | — | Piper Sandler | $133 → $145 | Reiterates | Overweight → Overweight | |||
04/17/2025 | — | RBC Capital | $140 → $145 | Maintains | Outperform | |||
04/17/2025 | — | Wells Fargo | $136 → $147 | Maintains | Overweight | |||
04/17/2025 | — | Morgan Stanley | $117 → $127 | Maintains | Equal-Weight | |||
04/17/2025 | — | Barclays | $158 → $159 | Maintains | Overweight | |||
04/17/2025 | — | Stifel | $135 → $145 | Maintains | Buy | |||
04/17/2025 | — | Jefferies | $135 → $137 | Maintains | Hold | |||
04/16/2025 | — | Evercore ISI Group | $138 → $140 | Maintains | Outperform | |||
04/15/2025 | — | RBC Capital | $135 → $140 | Maintains | Outperform | |||
03/10/2025 | — | B of A Securities | $133 → $150 | Maintains | Buy | |||
03/04/2025 | — | Citigroup | $135 → $160 | Maintains | Buy | |||
03/04/2025 | — | Goldman Sachs | $138 → $154 | Maintains | Buy | |||
01/27/2025 | — | Barclays | $149 → $158 | Maintains | Overweight | |||
01/23/2025 | — | Jefferies | $125 → $135 | Maintains | Hold | |||
01/23/2025 | — | Bernstein | $135 → $138 | Maintains | Outperform | |||
01/23/2025 | — | RBC Capital | $135 → $135 | Reiterates | Outperform → Outperform | |||
01/23/2025 | — | Wells Fargo | $133 → $136 | Maintains | Overweight | |||
01/23/2025 | — | Stifel | $130 → $135 | Maintains | Buy | |||
01/23/2025 | — | UBS | $146 → $148 | Maintains | Buy | |||
01/22/2025 | — | BTIG | $139 → $140 | Maintains | Buy | |||
01/21/2025 | — | RBC Capital | $135 → $135 | Reiterates | Outperform → Outperform | |||
01/08/2025 | — | Bernstein | $138 → $135 | Maintains | Outperform | |||
01/02/2025 | — | Evercore ISI Group | $128 → $136 | Maintains | Outperform | |||
12/20/2024 | — | RBC Capital | $130 → $135 | Maintains | Outperform | |||
11/05/2024 | — | Barclays | $143 → $149 | Maintains | Overweight | |||
10/17/2024 | — | Bernstein | $133 → $138 | Maintains | Outperform | |||
10/17/2024 | — | UBS | $143 → $146 | Maintains | Buy | |||
10/17/2024 | — | Jefferies | $120 → $125 | Maintains | Hold | |||
10/17/2024 | — | Mizuho | $115 → $130 | Maintains | Neutral | |||
10/17/2024 | — | Piper Sandler | $131 → $133 | Maintains | Overweight | |||
10/17/2024 | — | Morgan Stanley | $107 → $117 | Maintains | Equal-Weight | |||
10/16/2024 | — | Stifel | $125 → $130 | Maintains | Buy | |||
10/16/2024 | — | Evercore ISI Group | $124 → $128 | Maintains | Outperform | |||
10/16/2024 | — | BTIG | $135 → $139 | Maintains | Buy | |||
10/14/2024 | — | Raymond James | $122 → $129 | Maintains | Outperform | |||
10/08/2024 | — | RBC Capital | $125 → $130 | Maintains | Outperform | |||
10/08/2024 | — | Oppenheimer | → $130 | Initiates | → Outperform | |||
10/01/2024 | — | Evercore ISI Group | $120 → $124 | Maintains | Outperform | |||
09/26/2024 | — | Jefferies | $120 → $120 | Reiterates | Hold → Hold | |||
09/19/2024 | — | Piper Sandler | → $131 | Initiates | → Overweight | |||
08/27/2024 | — | Jefferies | $112 → $120 | Maintains | Buy | |||
08/22/2024 | — | Citigroup | $119 → $127 | Maintains | Buy | |||
07/29/2024 | — | Barclays | $140 → $143 | Maintains | Overweight | |||
07/02/2024 | — | Evercore ISI Group | $125 → $120 | Maintains | Outperform | |||
06/04/2024 | — | RBC Capital | $125 → $125 | Reiterates | Outperform → Outperform | |||
05/30/2024 | — | Goldman Sachs | → $121 | Initiates | → Buy | |||
05/22/2024 | — | Citigroup | $128 → $119 | Maintains | Buy | |||
04/22/2024 | — | Barclays | $141 → $140 | Maintains | Overweight | |||
04/18/2024 | — | RBC Capital | $128 → $125 | Maintains | Outperform | |||
04/04/2024 | — | Evercore ISI Group | $120 → $125 | Maintains | Outperform | |||
04/03/2024 | — | Citigroup | $126 → $128 | Maintains | Buy | |||
02/14/2024 | — | RBC Capital | $128 → $128 | Reiterates | Outperform → Outperform | |||
01/26/2024 | — | Barclays | $133 → $141 | Maintains | Overweight | |||
01/25/2024 | — | Wells Fargo | $131 → $133 | Maintains | Overweight | |||
01/25/2024 | — | RBC Capital | $128 → $128 | Reiterates | Outperform → Outperform | |||
01/25/2024 | — | Citigroup | $123 → $126 | Maintains | Buy | |||
01/25/2024 | — | Raymond James | $124 → $127 | Maintains | Outperform | |||
01/16/2024 | — | Wells Fargo | $121 → $131 | Maintains | Overweight | |||
01/11/2024 | — | RBC Capital | $119 → $128 | Maintains | Outperform | |||
01/03/2024 | — | Raymond James | $110 → $124 | Maintains | Outperform | |||
12/13/2023 | — | Wells Fargo | $116 → $121 | Maintains | Overweight | |||
12/11/2023 | — | Citigroup | $122 → $123 | Maintains | Buy | |||
10/19/2023 | — | Barclays | $132 → $133 | Maintains | Overweight | |||
10/19/2023 | — | Morgan Stanley | $112 → $107 | Maintains | Equal-Weight | |||
10/19/2023 | — | Wells Fargo | $136 → $116 | Maintains | Overweight | |||
10/19/2023 | — | Raymond James | $123 → $110 | Maintains | Outperform | |||
10/02/2023 | — | Jefferies | $120 → $112 | Maintains | Hold | |||
10/02/2023 | — | Citigroup | $130 → $122 | Maintains | Buy | |||
07/24/2023 | — | Barclays | $127 → $132 | Maintains | Overweight | |||
07/21/2023 | — | Morgan Stanley | $112 → $112 | Reiterates | Equal-Weight → Equal-Weight | |||
07/21/2023 | — | Mizuho | $110 → $115 | Assumes | Neutral → Neutral | |||
07/21/2023 | — | Wolfe Research | — | Upgrade | Underperform → Peer Perform | |||
05/30/2023 | — | Morgan Stanley | → $112 | Assumes | → Equal-Weight | |||
04/20/2023 | — | UBS | $117 → $130 | Maintains | Buy | |||
04/20/2023 | — | Raymond James | $116 → $123 | Maintains | Outperform |
FAQ
Quel est le cours indicatif de l'action Abbott Laboratories (ABT) ?
Le dernier objectif de prix pour Abbott Laboratories (NYSE:ABT) a été rapporté par Barclays le octobre 17, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $162.00 s'attendant à ce que ABT se rise dans les 12 prochains mois (un possible changement de 30.92% upside). 50 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Abbott Laboratories (ABT) ?
La dernière note d'analyste pour Abbott Laboratories (NYSE:ABT) a été fournie par Barclays, et Abbott Laboratories maintenu leur note overweight.
Quand a eu lieu la dernière mise à niveau pour Abbott Laboratories (ABT) ?
La dernière amélioration pour Abbott Laboratories a eu lieu le juillet 18, 2025 lorsque Jefferies a augmenté leur objectif de prix à $145. Jefferies avait précédemment a hold pour Abbott Laboratories.
Quand a eu lieu la dernière dégradation pour Abbott Laboratories (ABT) ?
Il n'y a pas de dernière réduction pour Abbott Laboratories.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Abbott Laboratories (ABT) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Abbott Laboratories, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Abbott Laboratories a été déposée le octobre 17, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 17, 2026.
La note d'analyste pour Abbott Laboratories (ABT) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Abbott Laboratories (ABT) était un maintenu avec un objectif de prix de $159.00 à $162.00. Le prix actuel de Abbott Laboratories (ABT) est de $123.74, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.